AR008864A1 - DERIVADOS DE DIAMINO-1,3,5-TRIAZINA SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS, PROCEDIMIENTO PARA LA PREPARACION DE DICHAS COMPOSICIONES, EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO UTIL PARA INFECCIONES DE HIV, E INTERMEDIARIO uTIL PARA PREPA - Google Patents
DERIVADOS DE DIAMINO-1,3,5-TRIAZINA SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS, PROCEDIMIENTO PARA LA PREPARACION DE DICHAS COMPOSICIONES, EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO UTIL PARA INFECCIONES DE HIV, E INTERMEDIARIO uTIL PARA PREPAInfo
- Publication number
- AR008864A1 AR008864A1 ARP970104503A ARP970104503A AR008864A1 AR 008864 A1 AR008864 A1 AR 008864A1 AR P970104503 A ARP970104503 A AR P970104503A AR P970104503 A ARP970104503 A AR P970104503A AR 008864 A1 AR008864 A1 AR 008864A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- preparation
- compounds
- compositions
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical class NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 title abstract 2
- 208000031886 HIV Infections Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- -1 hydroxy, amino Chemical group 0.000 abstract 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- APHFXDBDLKPMTA-UHFFFAOYSA-N Art1 Natural products CCCCCCCCCC(=O)c1c(CC(O)=O)cc2cc(O)cc(O)c2c1O APHFXDBDLKPMTA-UHFFFAOYSA-N 0.000 abstract 1
- 101100047770 Mus musculus Tspan32 gene Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000001118 alkylidene group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000000798 anti-retroviral effect Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Abstract
Compuestos derivados de diamino-1,3,5-triazina sustituida que tienen la formula (1), las sales de adicion farmacéuticamente aceptables de los mismos ya las formas estereoquímicamente isoméricas de los mismos donde R1 y R2 están cada unoindepen dientemente seleccionados de hidrogeno, hidroxi, amino, alquiloC1-C6 opcionalmente sustituido; alquiloxi C1-C6; alquilcarbonilo C1-C6; alquiloxicarbonil C1-C6 Ar1 mono o di (alquilo C1-C6) amino; aminocarbonilomono o di (alquilo C1-C6);dihid ro -2(3H)-furanona; o R1 y R2 tomados conjuntamente pueden formar un anillo pirrolidinilo, piperidinilo, morfolinilo,ácido o mono o di (alquilo C1-C6) amino alquilideno C1-C4; R3 es hidrogeno. Ar1 alquilcarbonilo C1-C6, alquilo C1-C6, alquiloxi C1-C6-carbonilo, alquilo C1-C6substituido con alquiloxicarbonilo C1-C6; y R4, R5, R6, R7 y R8 están cada uno independientemente seleccionados de hidrogeno, halo, alquilo C1-C6, alquiloxiC1-C6, ciano, aminocarbonilo, nitro, amino, trialometiloo trialometiloxi; L es alquilo C1-C10 opcionalmente sustituido; alquenilo C3-C10; alquinilo C3-C10 ycicloalquilo C3-C7; Art1 es fenilo opcionalmente sustituido, para la manufactura de un medicamento para el tratamiento de individuos que suf rendeinfeccion causada por HIV (Virus de Inmunodeficiencia Humana). Además se refiere a nuevos compuestos que constituyen un subgrupo de los compuestos deformula (I), a su procedimiento de preparacion, a las composiciones que las comprenden, alprocedimiento de prepracion de dichas composiciones, al uso dedichos compuestos para la manufactur de un medicamento para el tratamiento de individuos que sufren de infeccion causada por HIV (Virus de InmunodeficienciaHumana) y la combinacion dedicho compuesto con un compuesto anti-retroviral y un producto que los contiene.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2726096P | 1996-10-01 | 1996-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR008864A1 true AR008864A1 (es) | 2000-02-23 |
Family
ID=21836641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970104503A AR008864A1 (es) | 1996-10-01 | 1997-09-30 | DERIVADOS DE DIAMINO-1,3,5-TRIAZINA SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS, PROCEDIMIENTO PARA LA PREPARACION DE DICHAS COMPOSICIONES, EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO UTIL PARA INFECCIONES DE HIV, E INTERMEDIARIO uTIL PARA PREPA |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US6380194B1 (es) |
| EP (1) | EP0834507B1 (es) |
| JP (1) | JP4127882B2 (es) |
| KR (1) | KR100478846B1 (es) |
| CN (1) | CN1083438C (es) |
| AP (1) | AP914A (es) |
| AR (1) | AR008864A1 (es) |
| AT (1) | ATE267179T1 (es) |
| AU (1) | AU740809B2 (es) |
| BR (1) | BR9704937A (es) |
| CA (1) | CA2216486A1 (es) |
| CZ (1) | CZ297333B6 (es) |
| DE (1) | DE69729153T2 (es) |
| DK (1) | DK0834507T3 (es) |
| EE (1) | EE03826B1 (es) |
| ES (1) | ES2221679T3 (es) |
| HR (1) | HRP970526B1 (es) |
| HU (1) | HU225270B1 (es) |
| ID (1) | ID19599A (es) |
| IL (1) | IL121849A (es) |
| MY (1) | MY123803A (es) |
| NO (1) | NO311614B1 (es) |
| NZ (1) | NZ328854A (es) |
| OA (1) | OA10620A (es) |
| PL (1) | PL190155B1 (es) |
| PT (1) | PT834507E (es) |
| RU (1) | RU2186774C2 (es) |
| SG (1) | SG53075A1 (es) |
| SI (1) | SI0834507T1 (es) |
| SK (1) | SK285241B6 (es) |
| TR (1) | TR199701070A2 (es) |
| TW (1) | TW411335B (es) |
| ZA (1) | ZA978766B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO311614B1 (no) | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
| AU762523C (en) | 1998-11-10 | 2004-02-12 | Janssen Pharmaceutica N.V. | HIV replication inhibiting pyrimidines |
| IL143024A0 (en) * | 1998-11-10 | 2002-04-21 | Janssen Pharmaceutica Nv | 2,4-disubstituted triazine derivatives |
| DE19945982A1 (de) | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
| DE60025837T2 (de) * | 1999-09-24 | 2006-11-02 | Janssen Pharmaceutica N.V. | Antivirale feste dispersionen |
| JP4794793B2 (ja) * | 1999-12-28 | 2011-10-19 | ファーマコペイア， インコーポレイテッド | Ｎ−ヘテロ環ＴＮＦ−α発現阻害剤 |
| US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| JP5230050B2 (ja) * | 2000-05-08 | 2013-07-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｈｉｖ複製阻害剤 |
| EP1282607B1 (en) | 2000-05-08 | 2015-11-11 | Janssen Pharmaceutica NV | Prodrugs of hiv replication inhibiting pyrimidines |
| KR20040100835A (ko) | 2001-02-15 | 2004-12-02 | 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 | 안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법 |
| EP1409463B1 (en) * | 2001-06-26 | 2010-02-24 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
| US6958211B2 (en) | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| BR0213791A (pt) | 2001-11-01 | 2004-12-07 | Janssen Pharmaceutica Nv | Derivados de amida como inibidores de glicogênio sintase quinase 3-beta |
| EA007298B1 (ru) | 2001-11-01 | 2006-08-25 | Янссен Фармацевтика Н.В. | Гетероариламины в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3) |
| JP2005531566A (ja) | 2002-05-16 | 2005-10-20 | サイトビア インコーポレイティッド | カスパーゼ活性化剤およびアポトーシス誘導物質としての置換４−アリール−４ｈ−ピロロ［２，３−ｈ］クロメンおよび類似体ならびにそれらの使用 |
| US7476741B2 (en) * | 2002-05-16 | 2009-01-13 | Cytovia, Inc. | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| CN1747941A (zh) * | 2003-02-07 | 2006-03-15 | 詹森药业有限公司 | 抑制hiv的1,2,4－三嗪 |
| CL2004000306A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
| WO2005003103A2 (en) * | 2003-06-30 | 2005-01-13 | Astrazeneca Ab | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases |
| ES2442857T3 (es) | 2004-08-10 | 2014-02-13 | Janssen Pharmaceutica Nv | Derivados de 1,2,4-triazin-6-ona inhibidores de VIH |
| CA2578995A1 (en) * | 2004-09-03 | 2006-03-09 | Prometic Biosciences Inc. | 2,4,6-triamino-s-triazine-based compounds which bind to the tail (fc) portion of immunoglobulins and their use |
| CA2573976C (en) | 2004-09-30 | 2014-04-29 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines |
| EP1797047B1 (en) | 2004-09-30 | 2012-01-25 | Tibotec Pharmaceuticals | Hiv inhibiting 5-substituted pyrimidines |
| MX2007003797A (es) | 2004-09-30 | 2007-04-23 | Tibotec Pharm Ltd | 5-heterociclil pirimidinas inhibidoras del virus de inmunodeficiencia humana. |
| KR20070085286A (ko) | 2004-10-29 | 2007-08-27 | 티보텍 파마슈티칼즈 리미티드 | Ｈｉｖ를 저해하는 바이사이클릭 피리미딘 유도체 |
| JP5118029B2 (ja) | 2005-06-14 | 2013-01-16 | タイゲン バイオテクノロジー カンパニー，リミテッド | ピリミジン化合物 |
| US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| BRPI0709690B8 (pt) | 2006-03-30 | 2021-05-25 | Janssen R & D Ireland | 5-amido pirimidinas substituídas e composição farmacêutica que as compreende |
| KR20090094073A (ko) | 2006-12-29 | 2009-09-03 | 티보텍 파마슈티칼즈 리미티드 | Ｈｉｖ를 억제하는 6-치환된 피리미딘 |
| CN101573342A (zh) * | 2006-12-29 | 2009-11-04 | 泰博特克药品有限公司 | 抑制hiv的5,6-取代的嘧啶类化合物 |
| BRPI0810921A2 (pt) * | 2007-04-30 | 2014-10-29 | Prometic Biosciences Inc | Derivados de triazina, composições contendo tais derivados e métodos de tratamento de câncer e doenças autoimunes usando tais compostos |
| HUE025179T2 (en) * | 2008-04-21 | 2016-02-29 | Taigen Biotechnology Co Ltd | Heterocyclic Compounds |
| US9023834B2 (en) | 2008-11-13 | 2015-05-05 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
| US9058223B2 (en) * | 2011-04-22 | 2015-06-16 | Microsoft Technology Licensing Llc | Parallel entropy encoding on GPU |
| EP2912024B1 (en) * | 2012-10-24 | 2016-07-20 | Basf Se | Herbicidal azines |
| CN106458937A (zh) * | 2014-04-11 | 2017-02-22 | 巴斯夫欧洲公司 | 作为除草剂的二氨基三嗪衍生物 |
| WO2016059647A2 (en) * | 2014-10-13 | 2016-04-21 | SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) | Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1 |
| CN105837525B (zh) * | 2016-03-25 | 2019-05-28 | 浙江工业大学 | 2,4-二胺-1,3,5-三嗪类化合物及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE226474C (es) | ||||
| US2309663A (en) * | 1943-01-26 | Process fok preparing substituted | ||
| US2817814A (en) | 1953-08-13 | 1957-12-24 | Gen Electric | Corona detection probe |
| US2817614A (en) * | 1953-10-26 | 1957-12-24 | Monsanto Chemicals | Internally plasticized melamine resins and laminates made therewith |
| GB771327A (en) | 1953-10-26 | 1957-03-27 | Monsanto Chemicals | Production of heat hardenable melamine-formaldehyde condensation products |
| JPS4927592B1 (es) * | 1970-05-13 | 1974-07-18 | ||
| GB1390235A (en) | 1971-08-07 | 1975-04-09 | Kakenyaku Kako Kk | 2-amino-4,6substituted-s triazines and methods for their preparation |
| DE3724379A1 (de) * | 1987-07-23 | 1989-02-02 | Bayer Ag | Verfahren zur herstellung feinteiliger magnetischer hexaferritpigmente |
| DK0411153T3 (es) * | 1989-02-20 | 1997-02-10 | Idemitsu Kosan Co | |
| HUT69722A (en) * | 1991-11-12 | 1995-09-28 | Pfizer | Triazine derivatives for enhancing antitumor activity |
| US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| RU2153494C2 (ru) * | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
| NO311614B1 (no) * | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
-
1997
- 1997-09-22 NO NO19974368A patent/NO311614B1/no unknown
- 1997-09-23 SG SG1997003520A patent/SG53075A1/en unknown
- 1997-09-23 CZ CZ0299397A patent/CZ297333B6/cs not_active IP Right Cessation
- 1997-09-24 SI SI9730663T patent/SI0834507T1/xx unknown
- 1997-09-24 AT AT97202917T patent/ATE267179T1/de not_active IP Right Cessation
- 1997-09-24 DK DK97202917T patent/DK0834507T3/da active
- 1997-09-24 DE DE69729153T patent/DE69729153T2/de not_active Expired - Fee Related
- 1997-09-24 ES ES97202917T patent/ES2221679T3/es not_active Expired - Lifetime
- 1997-09-24 PT PT97202917T patent/PT834507E/pt unknown
- 1997-09-24 EP EP97202917A patent/EP0834507B1/en not_active Expired - Lifetime
- 1997-09-25 CA CA002216486A patent/CA2216486A1/en not_active Abandoned
- 1997-09-26 EE EE9700253A patent/EE03826B1/xx not_active IP Right Cessation
- 1997-09-26 NZ NZ328854A patent/NZ328854A/xx unknown
- 1997-09-26 AU AU39266/97A patent/AU740809B2/en not_active Ceased
- 1997-09-26 US US08/938,602 patent/US6380194B1/en not_active Expired - Fee Related
- 1997-09-29 IL IL12184997A patent/IL121849A/xx not_active IP Right Cessation
- 1997-09-29 MY MYPI97004540A patent/MY123803A/en unknown
- 1997-09-29 JP JP27938797A patent/JP4127882B2/ja not_active Expired - Fee Related
- 1997-09-29 KR KR1019970049662A patent/KR100478846B1/ko not_active Expired - Fee Related
- 1997-09-29 SK SK1319-97A patent/SK285241B6/sk unknown
- 1997-09-29 ID IDP973312A patent/ID19599A/id unknown
- 1997-09-29 AP APAP/P/1997/001109A patent/AP914A/en active
- 1997-09-30 HR HR970526A patent/HRP970526B1/xx not_active IP Right Cessation
- 1997-09-30 HU HU9701596A patent/HU225270B1/hu not_active IP Right Cessation
- 1997-09-30 TW TW086114172A patent/TW411335B/zh not_active IP Right Cessation
- 1997-09-30 TR TR97/01070A patent/TR199701070A2/xx unknown
- 1997-09-30 AR ARP970104503A patent/AR008864A1/es active IP Right Grant
- 1997-09-30 CN CN97121454A patent/CN1083438C/zh not_active Expired - Fee Related
- 1997-09-30 RU RU97116200/04A patent/RU2186774C2/ru not_active IP Right Cessation
- 1997-09-30 PL PL97322369A patent/PL190155B1/pl not_active IP Right Cessation
- 1997-09-30 ZA ZA978766A patent/ZA978766B/xx unknown
- 1997-09-30 BR BR9704937-9A patent/BR9704937A/pt not_active Application Discontinuation
- 1997-10-01 OA OA70094A patent/OA10620A/en unknown
-
2001
- 2001-11-15 US US10/002,456 patent/US6858609B2/en not_active Expired - Fee Related
-
2003
- 2003-03-26 US US10/397,760 patent/US6962916B2/en not_active Expired - Fee Related
-
2005
- 2005-08-12 US US11/203,325 patent/US7449575B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR008864A1 (es) | DERIVADOS DE DIAMINO-1,3,5-TRIAZINA SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS, PROCEDIMIENTO PARA LA PREPARACION DE DICHAS COMPOSICIONES, EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO UTIL PARA INFECCIONES DE HIV, E INTERMEDIARIO uTIL PARA PREPA | |
| EA200000990A1 (ru) | Вич-ингибирующие производные пиримидина | |
| AR018169A1 (es) | Uso de compuestos derivados trisustituidos de 1,3,5-triazina para la elaboracion de un medicamento, compuestos derivados de los mismos, un procesopara su preparacion, una composicion farmaceutica que los comprende, un proceso para su preparacion, la combinacion de los mismos con un compuesto antiret | |
| AR014785A1 (es) | Derivados de pirimidina, uso de dichos derivados para la preparacion de medicamentos para el tratamiento de hiv,composicion farmaceutica que los comprende,procedimiento para prepararla, procedimiento para preparar dichos derivados, e intermediarios utiles en la preparacion de dichos derivados. | |
| ES2178037T3 (es) | Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen. | |
| AR024227A1 (es) | Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas | |
| ES2055860T3 (es) | Derivados 2-aminopirimidinona. | |
| PA8552901A1 (es) | Derivados de pirimidina inhibidores de vih | |
| ECSP066361A (es) | Derivados de piperazina | |
| AR012489A1 (es) | Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y | |
| ES2081187T3 (es) | Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| MX9204454A (es) | Derivados de tiourea para inhibir la replicacion del virus de inmunodeficiencia humana y formulado farmaceutico que los contiene. | |
| ES2123039T3 (es) | Nuevas 3-(hidroxi-bencilidenil)-indolin-2-onas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| UY28578A1 (es) | Derivados de amida | |
| AR038955A1 (es) | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso | |
| AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
| ATE184598T1 (de) | Enniatine und enniatinderivate zur bekämpfung von endoparasiten | |
| MXPA03005464A (es) | Agentes antivirales. | |
| PA8556801A1 (es) | Compuestos de imidazopiridin como moduladores de receptor 5-ht 4 | |
| CL2004000590A1 (es) | Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v | |
| TR199900732T2 (xx) | PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri. | |
| ES2058749T3 (es) | Derivados 2-aminopirimidinona. | |
| BR0315958A (pt) | Composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
| NO930143L (no) | Piperidinforbindelser, deres fremstilling og bruk | |
| AR049405A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |